Upcoming Advances for GU Cancers

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.

A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Catch up on insights into the global development of breast cancer treatments in the global spotlight.

Peter E. Fecci, MD, PhD, discusses unmet needs in glioblastoma management and the early promise of CAR T-cell therapy in this disease.